Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 16Sarcoma 6Thoracic 3Other hematologic neoplasm 3Lymphoid 3Dermatologic 3Genitourinary 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1Myeloid 1Breast 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Cilengitide × Genitourinary × Clear all
NCT00121238 2016-04-28

Cilengitide in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00103337 2013-02-28

Cilengitide in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
106 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡